Track Recursion Pharmaceuticals, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Recursion Pharmaceuticals, Inc. RXRX · Stock Open Recursion Pharmaceuticals, Inc. in new tab

3.19 USD
EPS
-0.86
P/B
1.97
ROE
-48.72
Beta
1.15
Target Price
7.32 USD
Recursion Pharmaceuticals, Inc. logo

Recursion Pharmaceuticals, Inc.

🧾 Earnings Recap – Q3 2026

Recursion shares fell 3.9% after earnings, suggesting investors focused on the early, limited clinical evidence rather than the company’s platform and partnership progress. REC-1245 has shown only a small number of partial responses, while the transcript provides no new financial or clinical guidance that clearly explains the selloff.

  • REC-4881’s updated FAP data showed continued reductions in polyp burden, including in the upper GI tract and among larger, higher-risk polyps; management reported mostly Grade 1 or 2 adverse events and no additional discontinuations.
  • REC-1245 showed early single-agent activity in heavily pretreated solid-tumor patients: two confirmed and one unconfirmed partial response.
  • Sanofi optioned a potential first-in-class oral I&I candidate; phase I is expected to begin in 2027, and the option triggered a $10 million payment.
  • Recursion said it completed a $200 million financing, expects cash runway into 2029, lowered 2026 cash operating expense guidance from $390 million to $375 million, and expects 2027 expense below $360 million.
  • The company cited operating-efficiency gains, including 80%–90% fewer compounds synthesized versus industry benchmarks and trial enrollment 30%–60% faster.
📅
Loading chart...
Key Metrics
Earnings dateMarch 3, 2027
EPS-0.86
Book Value1.61
Price to Book1.97
Debt/Equity8.25
% Insiders2.530%
Growth
Revenue Growth2.59%
Estimates
Forward P/E-3.94
Forward EPS-0.81
Target Mean Price7.32

DCF valuation

Model fair value for Recursion Pharmaceuticals, Inc. (RXRX)
Result
Sign in to run the valuation for RXRX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
6 analysts · consensus Buy · mean target 7.32 USD (low 4.00, high 10.00) · as of 14 Nov 2026
Low 4.00
Mean 7.32
High 10.00
Price 3.19
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Recursion Pharmaceuticals, Inc. Logo Recursion Pharmaceuticals, Inc. Analysis (RXRX)

United States Health Care Official Website Stock

Is Recursion Pharmaceuticals, Inc. a good investment? Recursion Pharmaceuticals, Inc. (RXRX) is currently trading at 3.19 USD. Market analysts have a consensus price target of 7.32 USD. This suggests a potential upside from current levels.

Earnings Schedule: Recursion Pharmaceuticals, Inc. is expected to release its next earnings report on March 3, 2027. The market consensus estimate for Forward EPS is -0.81.

Investor FAQ

Does Recursion Pharmaceuticals, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Recursion Pharmaceuticals, Inc.?

Recursion Pharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 3, 2027. The company currently has a trailing EPS of -0.86.

Company Profile

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Exchange Ticker
NMS (United States) RXRX
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion